NVDA
NVIDIA
135.910 TSLA
Tesla
394.740 PLTR
Palantir
67.260 AMD
Advanced Micro Devices
116.040 AAPL
Apple
236.850 James van Geelen from Citrinitas Capital said, "If GLP-1 drugs have a 30% penetration rate in the obese population, the obesity rate in the United States would be lower than it was in 1997. And that could happen over the course of two or three years."
"We expect new therapies launching beginning in 2026 from firms including Amgen and Pfizer could grow to roughly one-quarter of the market by 2032," Morningstar said.
DelgadilloJoe : Hi